on Exxel Pharma, Inc.
Exxel Pharma to Showcase in Virtual Investor Lunch Break
Exxel Pharma, Inc., specializing in developing treatments for chronic cough, announced its participation in the upcoming Virtual Investor Lunch Break: The Exxel Opportunity. This event will feature Soren Mogelsvang, PhD, CEO of Exxel, who will present on Wednesday, May 8, 2024, at 12:00 PM ET.
The presentation will include an overview of the company, insights into its business prospects, and discussion on the potential of Exxel's therapies. Exxel is currently focusing on EX937, a novel treatment aimed at chronic cough patients. The event will be available via live webcast on the company’s website, with a replay accessible for 90 days post-event.
R. P.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Exxel Pharma, Inc. news